Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes

Journal of Immunotherapy

Volumn 23, Issue 1, 2000, Pages 67-74

  Contreras, Diana N ^a   Krammer, Peter H ^b   Potkul, Ronald K ^a   Bu, Ping ^a   Rossi, Juan L ^a   Kaufmann, Andreas M ^a   Gissmann, Lutz ^b   Qiao, Liang ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Cervical cancer; Cytotoxic T lymphocytes; Cytotoxicity; Interleukins

Indexed keywords

ANTIBODY; FAS ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 7;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CANCER;

ANTIGENS, CD95; APOPTOSIS; COCULTURE TECHNIQUES; FAS LIGAND PROTEIN; FEMALE; HELA CELLS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-7; JURKAT CELLS; LIGANDS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0033951633     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200001000-00009     Document Type: Article

References (28)

1. Ellem KAO, O'Rourke MGE, Johnson GR, et al. A case report: Immune responses and clinical course of the first human use of granulocyt/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997;44:10-20.
2. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-92.
3. Bellgrau D, Gold D, Selawry H, et al. A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-2.
4. French LE, Hahne M, Viard I, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in severeal immune-priviliged tissues and co-expression in adult tissues characterized by apoptotic cell turnover. J Cell Biology 1996;133:335-43.
5. Saas P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997;99:1173-8.
6. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
7. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med 1996;2:1361-6.
8. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med 1996;2:317-22.
9. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
10. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997;158: 4521-4.
11. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997;57:1007-12.
12. Kaufmann AK, Gissmann L, Street D, et al. Expression of CD80 enhances immunogenicity of cervical carcinoma cells in vitro. Cell Immunol 1996;169:246-51.
13. Kaufmann AK, Gissmann L, Schreckenberger C, Qiao L. Cervical carcinoma cells transfected with the CD80 gene elicit a primary CTL response specific for HPV 16 E7 antigens. Cancer Gene Therapy 1997;4:377-82.
14. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373:438-41.
15. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995;3:87-98.
16. Area MJ, Krauss JC, Aruga A, Cameron MJ, Chang AE. Concurrent induction of CD4+ and CD8+ T cells during tumor growth with anti-tumor reactivity in adoptive immunotherapy. J Immunother 1997;20:138-45.
17. Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and IL-2. J Clin Oncol 1997;15:796-807.
18. Kawakami Y, Hass GP, Lotze MT. Expansion of tumor-infiltrating lymphocytes from human tumors using the T cell growth factors IL-2 and IL-4. J Immunother 1993;14:336-47.
19. Yannelli JR, Hyatt C, McConnell S, et al. Growth of tumor-infiltrating lymphocytes from human solid tumors: summary of a 5-year experience. Int J Cancer 1996;65:413-21.
20. Greenberg PD, Nelson B, Gilbert M, et al. Genetic modification of T cell clones to improve the safety and efficacy of adoptive T cell therapy. Ciba Foundation Symposium 1994;187:212-13.
21. Melioli G, Ratio GB, Ponte M, et al. Treatment of stage IIB nonsmall cell lung cancer with surgery sollowed by infusion of tumor infiltrating lymphocytes and rIL-2: a pilot study. J Immunother 1996;19:224-30.
22. Nagashima S, Kashii Y, Reichert TE, et al. Human gastric carcinoma transduced with IL-2 gene: increased sensitivity to immune effector cells in vitro and in vivo. Int J Cancer 1997;72:174-83.
23. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Ann Rev Immunol 1995;13:399-415.
24. Armstrong TD, Clements VK, Martin BK, Ting JPY, Ostrand-Rosenberg S. MHC class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 1997;94:6886-91.
25. Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol 1996;156:3821-7.
26. Baskar S, Glimcher LH, Nabavi N, Jones RT, Ostrand-Rosenberg S. MHC class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995; 181:619-29.
27. Lin KY, Guarnierri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances MHC class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
28. Wu TC, Garnierri FG, Staveley-O'Carroll KF, et al. Engineering an intracellular pathway for MHC class II presentation of antigens. Proc Natl Acad Sci USA 1995;92:11671-5.